Verve Therapeutics (VERV)
Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. The compa...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 11.130
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- 0.00
- Turnover Ratio
- --
News
- Tip Ranks · Apr 29 at 09:35 AM
Verve Publishes 2026 AGM Notice and Maps Out Busy Investor Roadshow Calendar
- Pharmaceutical Technology · Apr 15 at 10:03 AM
FDA shares guide on genome editing best practices
- Simplywall · Apr 14 at 01:01 AM
European Growth Stocks Insiders Are Eager To Own
- Market Beat · Mar 23 at 06:32 PM
Digital Turbine Conference: CEO Says AI Agents Will Enhance Ad Tech, Not Replace It
- MorningStar · Mar 19 at 04:31 AM
CRISPR-Integrated Gene Editing Delivery Devices Market Outlook 2026-2036: Global Market to Reach USD 4.41 Billion by 2036 at 14.10% CAGR
- Tip Ranks · Mar 10 at 07:29 AM
Verve Group Taps LLM Chat Signals for Next-Gen Ad Targeting
